ESR1 and breast carcinoma: Nevertheless, most in vitro and in vivo studies indicate that activated AR exerts an anti-estrogenic, growth-inhibitory influence in ERα-positive luminal breast cancers, partly dependent on its ability to antagonize ERα signaling through several mechanisms [51,52].